Ventripoint to Issue Shares for Payment of Debenture Interest

Executive Summary

• Ventripoint Diagnostics Ltd. will satisfy $103,106.29 of accrued interest on multiple convertible debentures by issuing 1,145,627 common shares at a deemed price of $0.089 per share, subject to TSX Venture Exchange approval.
• The issued shares are subject to a hold period of four months and one day and will not result in any party obtaining control of the corporation.
• This transaction converts interest obligations into equity, preserving cash while modestly diluting existing shareholders.

Key Details

• Interest Paid: $103,106.29 accrued on convertible debentures issued on May 10 2024; June 28 2024; September 20 2024; January 17 2025; February 7 2025; March 21 2025.
• Shares Issued: 1,145,627 common shares to be issued as consideration for the interest payment.
• Deemed Share Price: $0.089 per share (subject to TSXV approval).
• Hold Period: Shares subject to a lock‑up of four months and one day from issuance.
• Control Impact: The issuance will not create a control person under TSX Venture Exchange rules.
• Interest Rate on Debentures: 10% per annum, payable semi‑annually.

Notable Quotes

(No executive quotes were included in the release.)